首站-论文投稿智能助手
典型文献
Protection from infection or disease?Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines
文献摘要:
How do we measure vaccine efficacy?The strictest but also easiest parameter to determine vaccine efficacy is its ability to block infection.Indeed,if a vaccine is able to block infection,this necessarily follows that it will also prevent both disease development and viral transmission.As a consequence,antibodies,specifically neutralising antibodies,have been used as the"gold standard"correlate of protection to measure SARS-CoV-2 vaccine efficacy,given their ability to block infection.Since SARS-CoV-2 infects cells by the binding of its spike protein to the host ACE-2 receptor,a vaccine that is able to induce a large quantity of antibodies able to block the interaction between the ACE-2 receptor and spike protein should theoretically be highly efficacious.Given this"antibody-centric"method of evaluating of a vaccine,it is clear why spike mRNA vaccines have to date been regarded the most effective COVID-19 vaccine in the market.
文献关键词:
作者姓名:
Anthony T.Tan;Joey Ming Er Lim;Antonio Bertoletti
作者机构:
Programme in Emerging Infectious Diseases,Duke-NUS Medical School,Singapore,169857,Singapore;Singapore Immunology Network,A*STAR,Singapore,138648,Singapore
文献出处:
引用格式:
[1]Anthony T.Tan;Joey Ming Er Lim;Antonio Bertoletti-.Protection from infection or disease?Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines)[J].中国病毒学,2022(06):783-785
A类:
easiest,neutralising
B类:
Protection,from,infection,disease,Re,evaluating,broad,immunogenicity,inactivated,SARS,CoV,vaccines,How,do,measure,efficacy,strictest,but,also,parameter,determine,its,ability,block,Indeed,able,this,necessarily,follows,that,will,prevent,both,development,viral,transmission,consequence,antibodies,specifically,have,been,used,gold,standard,correlate,protection,given,their,Since,infects,cells,by,binding,spike,protein,host,ACE,receptor,induce,large,quantity,interaction,between,should,theoretically,highly,efficacious,Given,antibody,centric,method,clear,why,date,regarded,most,effective,market
AB值:
0.546083
相似文献
An ultrapotent pan-β-coronavirus lineage B(β-CoV-B)neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Zezhong Liu;Wei Xu;Zhenguo Chen;Wangjun Fu;Wuqiang Zhan;Yidan Gao;Jie Zhou;Yunjiao Zhou;Jianbo Wu;Qian Wang;Xiang Zhang;Aihua Hao;Wei Wu;Qianqian Zhang;Yarning Li;Kaiyue Fan;Ruihong Chen;Qiaochu Jiang;Christian T.Mayer;Till Schoofs;Youhua Xie;Shibo Jiang;Yumei Wen;Zhenghong Yuan;Kang Wang;Lu Lu;Lei Sun;Qiao Wang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),School of Basic Medical Sciences;Shanghai Institute of Infectious Disease and Biosecurity;the Fifth People's Hospital of Shanghai;Shanghai Key Laboratory of Medical Epigenetics,International Co-laboratory of Medical Epigenetics and Metabolism(Ministry of Science and Technology);Institutes of Biomedical Sciences;Biosafety Level 3 Laboratory,Shanghai Medical College,Fudan University,Shanghai 200032,China;CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing 100101,China;Experimental Immunology Branch,Center for Cancer Research,National Cancer Institute,National Institutes of Health,Bethesda,MD 20892,USA;GSK Vaccines,1300 Wavre,Belgium
Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2
Yunqing Gu;Jun Cao;Xinyu Zhang;Hai Gao;Yuyan Wang;Jia Wang;Juan He;Xiaoyi Jiang;Jinlan Zhang;Guanghui Shen;Jie Yang;Xichen Zheng;Gaowei Hu;Yuanfei Zhu;Shujuan Du;Yunkai Zhu;Rong Zhang;Jianqing Xu;Fei Lan;Di Qu;Guoliang Xu;Yun Zhao;Dong Gao;Youhua Xie;Min Luo;Zhigang Lu-The Fifth People's Hospital of Shanghai,the Shanghai Key Laboratory of Medical Epigenetics,the International Co-laboratory of Medical Epigenetics and Metabolism,Ministry of Science and Technology,Institutes of Biomedical Sciences,Shanghai Institute of Infectious Diseases and Biosecurity,Shanghai Medical College,Fudan University,Shanghai,China;Institute of Pediatrics,Children's Hospital of Fudan University,Shanghai,China;Zhongshan-Xuhui Hospital,Fudan University,Shanghai,China;Key Laboratory of Medical Molecular Virology (MOE/MOH),School of Basic Medical Sciences,Shanghai Institute of Infectious Diseases and Biosecurity,Shanghai Medical College,Fudan University,Shanghai,China;State Key Laboratory of Molecular Biology,CAS Center for Excellence in Molecular Cell Science,Institute of Biochemistry and Cell Biology,Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences,Shanghai,China;State Key Laboratory of Cell Biology,Shanghai Key Laboratory of Molecular Andrology,CAS Center for Excellence in Molecular Cell Science,institute of Biochemistry and Ceil Biology,Shanghai institutes for Biological Sciences,Chinese Academy of Sciences,Shanghai,China;Shanghai Public Health Clinical Center,Fudan University,Shanghai,China
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
Jun Lan;Xinheng He;Yifei Ren;Ziyi Wang;Huan Zhou;Shilong Fan;Chenyou Zhu;Dongsheng Liu;Bin Shao;Tie-Yan Liu;Qisheng Wang;Linqi Zhang;Jiwan Ge;Tong Wang;Xinquan Wang-The Ministry of Education Key Laboratory of Protein Science,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,Collaborative Innovation Center for Biotherapy,School of Life Sciences,Tsinghua University,Beijing,China;Microsoft Research Asia,Beijing,China;Shanghai Synchrotron Radiation Facility,Shanghai Advanced Research Institute,Chinese Academy of Sciences,Shanghai,China;Department of Chemistry,Tsinghua University,Beijing,China;Center for Global Health and Infectious Diseases,Comprehensive AIDS Research Center,and Beijing Advanced Innovation Center for Structural Biology,School of Medicine,Tsinghua University,Beijing,China
Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron
Huan Ma;Xinghai Zhang;Peiyi Zheng;Peter H.Dube;Weihong Zeng;Shaohong Chen;Qingyu Cheng;Yunru Yang;Yan Wu;Junhui Zhou;Xiaowen Hu;Yan Xiang;Huajun Zhang;Sandra Chiu;Tengchuan Jin-Department of Pulmonary and Critical Care Medicine,The First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;State Key Laboratory of Virology,Wuhan Institute of Virology,Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan,Hubei,China;Laboratory of Structural Immunology,CAS Key Laboratory of Innate Immunity and Chronic Disease,Hefei National Laboratory for Physical Sciences at Microscale,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei,Anhui,China;Department of Microbiology,Immunology and Molecular Genetics,University of Texas Health Science Center at San Antonio,San Antonio,TX,USA;University of Chinese Academy of Sciences,Beijing,China;Institute of Health and Medicine,Hefei Comprehensive National Science Center,Hefei,Anhui,China
A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
Yingdan Wang;Wuqiang Zhan;Jiangyan Liu;Yanqun Wang;Xiang Zhang;Meng Zhang;Lin Han;Yunping Ma;Lu Lu;Yumei Wen;Zhenguo Chen;Jincun Zhao;Fan Wu;Lei Sun;Jinghe Huang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)and Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Fifth People's Hospital,Shanghai Public Health Clinical Center,Institutes of Biomedical Sciences,School of Basic Medical Sciences,Fudan University,Shanghai,China;Shanghai Immune Therapy Institute,Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital,Shanghai,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Wei Pang;Ying Lu;Yan-Bo Zhao;Fan Shen;Chang-Fa Fan;Qian Wang;Wen-Qiang He;Xiao-Yan He;Ze-Kai Li;Tao-Tao Chen;Cui-Xian Yang;You-Zhi Li;Si-Xuan Xiao;Zu-Jiang Zhao;Xu-Sheng Huang;Rong-Hua Luo;Liu-Meng Yang;Mi Zhang;Xing-Qi Dong;Ming-Hua Li;Xiao-Li Feng;Qing-Cui Zhou;Wang Qu;Shibo Jiang;Songying Ouyang;Yong-Tang Zheng-Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences/Key Laboratory of Bioactive Peptides of Yunnan Province,KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China;University of the Chinese Academy of Sciences,Beijing,China;The Key Laboratory of Innate Immune Biology of Fujian Province,Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation,Biomedical Research Center of South China,Key Laboratory of OptoElectronic Science and Technology for Medicine of Ministry of Education,College of Life Sciences,Fujian Normal University,Fuzhou,Fujian,China;Division of Animal Model Research,Institute for Laboratory Animal Resources,National Institutes for Food and Drug Control,Beijing,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),Shanghai Institute of Infectious Disease and Biosecurity,School of Basic Medical Sciences,Fudan University,Shanghai,China;Yunnan Provincial Infectious Disease Hospital,Kunming,Yunnan,China;Kunming National High-level Biosafety Research Center for Non-human Primates,Center for Biosafety Mega-Science,Kunming Institute of Zoology,Chinese Academy of Sciences,Kunming,Yunnan,China
Early assessment of the safety and immunogenicity of a third dose(booster)of COVID-19 immunization in Chinese adults
Yuntao Zhang;Yunkai Yang;Niu Qiao;Xuewei Wang;Ling Ding;Xiujuan Zhu;Yu Liang;Zibo Han;Feng Liu;Xinxin Zhang;Xiaoming Yang-China National Biotec Group Company Limited,Beijing 100024,China;Shanghai Institute of Hematology,State Key Laboratory of Medical Genomics,National Research Center for Translational Medicine at Shanghai,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Beijing Institute of Biological Products,China National Biotec Group Company Limited,Beijing 100176,China;National Vaccine and Serum Institute,China National Biotec Group Company Limited,Beijing 101111,China;Department of Infectious Diseases,Research Laboratory of Clinical Virology,Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。